BioMarin, Par settlement deal

BioMarin granted Endo's Par Pharmaceutical company non-exclusive U.S. rights to market Kuvan sapropterin as a generic starting Oct. 2020 or earlier. BioMarin said the deal, which covers 100mg tablets ...